Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
NASDAQ:GILD
GILD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$62.07 - $119.96
Previous CloseN/A
Volume1.95M
Average Volume (3M)9.87M
Market Cap
$127.50B
Enterprise Value$112.88B
Total Cash (Recent Filing)$7.93B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)21.6
Beta0.39
Next Earnings
Aug 05, 2025EPS Estimate
1.96Next Dividend Ex-Date
Jun 13, 2025Dividend Yield3.02%
Share Statistics
EPS (TTM)1.81
Shares Outstanding1,243,929,100
10 Day Avg. Volume9,866,267
30 Day Avg. Volume9,869,919
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)6.33
Price to Sales (P/S)0.00
P/FCF Ratio12.14
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue0.99
Enterprise Value/Gross Profit4.89
Enterprise Value/Ebitda4.80
Forecast
1Y Price Target
$120.53Price Target Upside17.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
---
Bulls Say, Bears Say
Bulls Say
Clinical Trials And ApprovalsASCENT-04 trial hit the primary endpoint of PFS in 1L mTNBC (PD-L1+), indicating progress in oncology.
Financial PerformanceThe 4% EPS beat was driven by solid cost controls, which more than offset the slight miss in total revenue.
Product PerformanceStrong growth was observed in the HIV drug Descovy, driven by market share gains and pricing advantages, contributing positively to the company’s overall performance.
Bears Say
Government Policy ImpactProposed government budget cuts could indirectly impact HIV/AIDS treatment and prevention services.
Oncology Segment ChallengesThe company faced continued pressure in its Oncology segment, particularly in the CAR-T business, with a notable miss for Trodelvy attributed to inventory issues.
Revenue ConcernsGilead Sciences experienced a revenue miss that has concerned investors, attributed to the first impact of the Part-D redesign.
---
Ownership Overview
0.09% Insiders
30.61% Mutual Funds
20.80% Other Institutional Investors
21.36% Public Companies and Individual Investors
GILD FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was $62.07 and its highest was $119.96 in the past 12 months.
What is Gilead Sciences’s market cap?
Gilead Sciences’s market cap is $127.50B.
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Aug 05, 2025 which is in 78 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Apr 24, 2025. The company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.78 by $0.03.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of $0.79 which represents an annual dividend yield of 3.02%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is 1.96.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,243,929,100 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of $1.81 in its last earnings report, beating expectations of $1.78. Following the earnings report the stock price went down -2.807%.
Which hedge fund is a major shareholder of Gilead Sciences?
Currently, no hedge funds are holding shares in GILD
---
Gilead Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$120.53 (17.59% Upside)
$120.53 (17.59% Upside)
Blogger Sentiment
Bullish
GILD Sentiment 93%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 911.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.71%
12-Months-Change
Fundamentals
Return on Equity
32.51%
Trailing 12-Months
Asset Growth
0.25%
Trailing 12-Months
Company Description
Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
---
GILD Company Deck
---
GILD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with strong growth in the HIV and liver disease segments, successful clinical trials, and promising product launches, contrasted by declines in overall product sales, Veclury, and oncology due to COVID-19 dynamics and competitive pressures. The company's strategic focus on pipeline and market expansion is promising but faces market challenges.Read More>---
GILD Revenue Breakdown
68.21% HIV
11.44% Oncology
10.51% Liver Disease
6.26% Veklury
3.59% Other
---
GILD Stock 12 Month Forecast
Average Price Target
$120.53
▲(17.59% Upside)
Technical Analysis
---